Parnax Lab Limited (BOM:506128)

India flag India · Delayed Price · Currency is INR
125.50
+7.00 (5.91%)
At close: Feb 12, 2026
Market Cap1.35B -19.8%
Revenue (ttm)2.05B +4.8%
Net Income110.28M -6.6%
EPS9.60 -6.6%
Shares Out11.49M
PE Ratio12.29
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume13,459
Average Volume6,099
Open118.50
Previous Close118.50
Day's Range118.00 - 130.00
52-Week Range81.00 - 145.00
Beta-0.04
RSI47.24
Earnings DateFeb 13, 2026

About Parnax Lab

Parnax Lab Limited engages in the manufacture and export of pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; cosmetic products; herbal products; and nutraceutical products. It also provides Oral Formulations, such as cough expectorants, antacids, antihistamines, multi-vitamins, enzyme preparations, pediatric formulations, formulations for geriatrics, highly viscous products, and suspensions. In addition, the company provid... [Read more]

Industry Pharmaceutical Preparations
Founded 1982
Employees 12
Stock Exchange Bombay Stock Exchange
Ticker Symbol 506128
Full Company Profile

Financial Performance

In fiscal year 2025, Parnax Lab's revenue was 1.88 billion, a decrease of -0.54% compared to the previous year's 1.89 billion. Earnings were 115.19 million, an increase of 19.87%.

Financial Statements